Cargando…

STARTRAC analyses of scRNAseq data from tumor models reveal T cell dynamics and therapeutic targets

Single-cell RNA sequencing is a powerful tool to examine cellular heterogeneity, novel markers and target genes, and therapeutic mechanisms in human cancers and animal models. Here, we analyzed single-cell RNA sequencing data of T cells obtained from multiple mouse tumor models by PCA-based subclust...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhatt, Dev, Kang, Boxi, Sawant, Deepali, Zheng, Liangtao, Perez, Kristy, Huang, Zhiyu, Sekirov, Laura, Wolak, Dan, Huang, Julie Y., Liu, Xian, DeVoss, Jason, Manzanillo, Paolo S., Pierce, Nathan, Zhang, Zemin, Symons, Antony, Ouyang, Wenjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Rockefeller University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8077174/
https://www.ncbi.nlm.nih.gov/pubmed/33900375
http://dx.doi.org/10.1084/jem.20201329
Descripción
Sumario:Single-cell RNA sequencing is a powerful tool to examine cellular heterogeneity, novel markers and target genes, and therapeutic mechanisms in human cancers and animal models. Here, we analyzed single-cell RNA sequencing data of T cells obtained from multiple mouse tumor models by PCA-based subclustering coupled with TCR tracking using the STARTRAC algorithm. This approach revealed various differentiated T cell subsets and activation states, and a correspondence of T cell subsets between human and mouse tumors. STARTRAC analyses demonstrated peripheral T cell subsets that were developmentally connected with tumor-infiltrating CD8(+) cells, CD4(+) Th1 cells, and T reg cells. In addition, large amounts of paired TCRα/β sequences enabled us to identify a specific enrichment of paired public TCR clones in tumor. Finally, we identified CCR8 as a tumor-associated T reg cell marker that could preferentially deplete tumor-associated T reg cells. We showed that CCR8-depleting antibody treatment provided therapeutic benefit in CT26 tumors and synergized with anti–PD-1 treatment in MC38 and B16F10 tumor models.